To the Editor:

We are writing in reference to the recent article published in the November 2020 issue of JPPT evaluating rapid infliximab infusions in the pediatric population. We feel there is an error in the authors' conclusion that “This study is the first of its kind to show rapid infliximab can be a well-tolerated alternative to standard 2- to 3-hour titrated infusion in both pediatric rheumatology and gastroenterology patients.” Three papers and 1 letter to the editor describing the safe use of rapid infusions of infliximab in pediatric gastroenterology and rheumatology patients were published in 2017 and 2018.2–5  This includes our prospective comparison of rapid infliximab in 66 patients receiving 545 infusions to a historical control group of 50 patients receiving 540 standard (2- to 3-hour) infusions. These 4 publications not cited by...

You do not currently have access to this content.